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Progressive human immunodeficiency virus type 1 (HIV-1) infection is often associated with high plasma
virus load (pVL) and impaired CD8 T-cell function; in contrast, CD8 T cells remain polyfunctional in
long-term nonprogressors. However, it is still unclear whether CD8 T-cell dysfunction is the cause or the
consequence of high pVLs. Here, we conducted a longitudinal functional and phenotypic analysis of virus-
specific CD8 T cells in a cohort of patients with chronic HIV-1 infection. During the initiation and mainte-
nance of successful antiretroviral therapy (ART), we assessed whether the level of pVL was associated with the
degree of CD8 T-cell dysfunction. Under viremic conditions, HIV-specific CD8 T cells were dysfunctional
with respect to cytokine secretion (gamma interferon, interleukin-2 [IL-2], and tumor necrosis factor alpha),
and their phenotype suggested limited potential for proliferation. During ART, cytokine secretion by HIV-
specific CD8 T cells was gradually restored, IL-7R and CD28 expression increased dramatically, and PD-1
levels declined. Thus, prolonged ART-induced reduction of viral replication and, hence, presumably antigen
exposure in vivo, allows a significant functional restoration of CD8 T cells with the appearance of polyfunc-
tional cells. These findings indicate that the level of pVL as a surrogate for antigen load has a dominant
influence on the phenotypic and functional profile of virus-specific CD8 T cells.
A large body of evidence indicates that virus-specific CD8
T-cell responses play an important role in controlling human
immunodeficiency virus (HIV) and simian immunodeficiency
virus (SIV) replication. During the acute phase of HIV/SIV
infection, partial control of viral replication is associated with
a marked expansion of virus-specific CD8 T cells in infected
individuals (2, 10, 14, 47). Furthermore, in vivo depletion of
CD8 T cells before or during SIV infection of rhesus ma-
caques leads to a massive increase in viremia (40, 65). More-
over, long-term nonprogression in HIV type 1 (HIV-1) infec-
tion is associated with both vigorous CD8 T-cell responses
(45, 60) and with specific HLA class I alleles (4, 16, 17, 43, 52,
64). Persistent HIV/SIV replication is also associated with mu-
tational escape at targeted CD8 T-cell epitopes, suggesting
an important selection pressure on the virus (2, 15, 31, 32, 44,
57, 62, 63). Ultimately, however, virus-specific CD8 T cells
are unable to control viral replication over prolonged periods
of time in the vast majority of HIV-infected patients and SIV-
infected macaques.
It has been demonstrated that HIV-specific CD8 T cells
from viremic patients are often dysfunctional; they usually
express low levels of perforin (7, 8, 19, 25, 72, 73), have a poor
ex vivo killing capacity (8, 20, 67, 72), and produce only a
limited spectrum of cytokines (11, 13, 24). In addition, their
proliferative capacity has been shown to be substantially re-
duced (51). The fact that both proliferation and perforin ex-
pression by HIV-specific CD8 T cells are superior in long-
term nonprogressors (LTNP) (51) may suggest a critical
relationship between CD8 T-cell functionality and plasma
virus load (pVL). Furthermore, LTNP exhibit increased fre-
quencies of polyfunctional HIV-specific T cells compared to
progressors (3, 13, 33). These cells are able to perform multiple
effector functions simultaneously, including the secretion of
several cytokines and chemokines as well as degranulation, and
are thought to be relevant for superior viral control in LTNP
(3, 13, 29, 33, 49). However, it is not entirely clear whether
improved T-cell functionality is the cause or the consequence
of reduced pVL in LTNP.
In the present study, we assessed whether modulation of
pVL by antiretroviral therapy (ART) induces important func-
tional and phenotypic changes in CD8 T cells from patients
with chronic HIV-1 infection. We also addressed the time
frame required for such changes to occur. Our longitudinal
study indicates that pVL as a surrogate for antigen load has a
profound influence on the functional capacities and pheno-
typic signatures of virus-specific CD8 T cells. After prolonged
ART, HIV-specific CD8 T cells significantly increased their
cytokine secretion capabilities, and substantial populations of
polyfunctional cells emerged; furthermore, these CD8 T cells
developed phenotypic profiles characteristic of resting memory
cells. These functional changes occurred slowly and required
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successful ART for a median duration of 30 months to de-
velop. However, the significance of this functional improve-
ment of CD8 T cells is unclear since previous studies have
firmly established that viral control is generally not increased
after cessation of ART in chronically infected patients (27, 28,
36, 53, 54, 56).
MATERIALS AND METHODS
Study individuals. Thirty-seven patients chronically infected with HIV-1 (sub-
type B) who were either ART naı¨ve (n  25) or had interrupted ART for 6
months (n  12) were included in the study. Of the latter, the median duration
without ART before study entry was 24 months (range, 8 to 66 months). Inclu-
sion criteria were as follows: pVL of 4,000 RNA copies/ml and a CD4 count of
50 cells/l. Three patients with minor inclusion criterion violations at baseline
remained in the study (patient 16 with a pVL of 3,970 copies/ml and patients 12
and 14 with CD4 counts of 49 cells/l). According to treatment history and
baseline resistance testing, all patients had the potential for complete viral
suppression (50 copies/ml) within 6 months of ART initiation. Twenty-five
patients, classified as the study group, initiated ART at week 0, while the re-
maining 12 patients, classified as the control group, remained untreated. Patient
29 stopped ART at week 5; therefore, later time points were not analyzed. The
ART regimen usually consisted of two nucleoside/nucleotide reverse transcrip-
tase inhibitors (NRTIs) combined with a protease inhibitor (n  15) or a
non-NRTI (n  8); two patients were treated with a triple-class combination
(two NRTIs plus protease inhibitor and non-NRTI). Blood samples from the
study group patients were taken at weeks 0, 2, 4, 12, and 24 as well as after a
median of 2.5 years (shown as 24 weeks) following the onset of ART. In the
control group, blood samples were taken at week 0, 12, and 24 as well as after a
median of 1.6 years (shown as 24 weeks) from the beginning of the study. pVL
was measured at every time point, and CD4 counts were measured at weeks 0, 12,
and 24 and at 1.6 or 2.5 years. The clinical characteristics of all patients are
summarized in Table 1. The study was approved by the local ethical committee,
TABLE 1. Baseline characteristics of patients
Treatment group Patientno. Gender
a Age (yrs) pVL (RNA copies/ml) CD4 count(cells/l)b ART
c HLA genotype
Therapy 01 M 43 48,500 185 3TC/TDF/EFV A02/B40/B44
02 M 39 374,000 158 AZT/3TC/EFV A02/A29/B07/B44
03 M 33 960,000 154 AZT/3TC/EFV A01/A02/B37/B15
05 F 34 202,500 121 AZT/3TC/ATVr A11/A68/B35/B39
06 M 32 90,000 147 AZT/3TC/LPVr A03/A11/B35
09 M 30 403,000 91 AZT/3TC/LPVr A02/A24/B18/B53
10 M 44 46,000 57 AZT/3TC/LPVr A30/A11/B15/B18
12 M 39 2,450,000 49 3TC/TDF/EFV/LPVr A01/A02/B51/B56
13a M 36 17,800 189 AZT/3TC/LPVr A02/A68/B08/B51
13b M 40 167,000 207 3TC/TDF/LPVr A02/A24/B27/B15
14 M 50 131,000 49 3TC/TDF/LPVr A01/A11/B08/B51
15 M 45 92,000 197 DDI/TDF/EFV A02/A03/B27/B57
17 M 45 6,680 186 DDI/TDF/EFV A24/A11/40
18 M 35 140,000 164 TDF/EFV/LPVr A02/A24/B35/B51
20 M 41 12,700 275 AZT/3TC/LPVr A02/A11/B57/B51
21 M 43 17,700 178 ABC/TDF/ATVr A01/A24/B49/B38
22 M 27 23,400 288 AZT/3TC/LPVr A03/B35
23 F 38 900,000 187 3TC/D4T/NFV B47/B42
24 M 37 211,000 334 3TC/TDF/EFV A03/A11/B07
25 M 44 42,600 219 ABC/TDF/EFV A03/B18/B35
26 M 31 2,080,000 152 3TC/TDF/EFV/LPVr A30/A29/B13/B44
28 M 30 137,000 135 AZT/3TC/EFV A01/A03/B08/B38
29 F 28 70,300 277 AZT/3TC/LPVr A01/A02/B08/B15
31 M 41 11,200 289 AZT/3TC/FPVr A02/A03/B07/B15
39 M 42 167000 548 AZT/3TC/LPVr NDd
Median (range) for
group (n  25)
39* (27–50) 131,000 (6,680–2,450,000) 185 (49–548)
Control 04 M 38 121,000 365 A26/A11/B13/B44
08 F 61 89,600 227 A02/A32/B07/B40
16 F 36 3,970 185 A30/A33/B35/B51
19 M 42 38,400 202 A02/B13/B27
27 M 37 127,000 252 A02/A03/B07/B44
30 M 27 147,000 342 A02/B08/B27
32 M 38 60,200 353 A01/A24/B47/B57
33 M 37 25,500 328 A01/A03/B08/B15
34 M 59 23,100 330 A01/A68/B44/B57
35 M 42 88,600 350 A01/A03/B08/B35
36 M 28 20,800 364 A24/A33/B44/B15
37 M 54 12,700 351 A02/A32/B07
Median (range) for
group (n  12)
38 (27–61) 49,300 (3,970–147,000) 336 (185–365)
a M, male; F, female. The ratio of female to male patients was 3/22 in the therapy group and 2/10 in the control group.
b CD4 count, absolute CD4 T cell count.
c AZT, zidovudine; 3TC, lamivudine; ABC, abacavir; DDI, didanosine; D4T, stavudine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; ATV, atazanavir; LPV,
lopinavir; FPV, Fos-amprenavir; r, ritonavir (booster dose).
d ND, not determined.
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and written informed consent from all subjects was obtained according to the
guidelines of the University Hospital, Zurich. HIV-seronegative donor samples
were obtained from the Stiftung Zu¨rcher Blutspendedienst, Swiss Red Cross.
HLA genotyping. HLA genotyping (Table 1) was performed at a diagnostic
laboratory by using sequence specific PCRs according to standard procedures.
DNA for typing was extracted using the Protrans DNA isolation kit (Protrans,
Germany).
Quantification of HIV-1 plasma virus load. Plasma HIV RNA was quantified
with an Amplicor HIV-1 Monitor test, version 1.5 (Roche Diagnostics, Rotkreuz,
Switzerland), with a modification leading to a detection limit of 40 copies/ml
(66).
Lymphocyte separation. Fresh peripheral blood mononuclear cells (PBMCs)
were isolated from whole blood using Ficoll-Hypaque density gradient centrifu-
gation and were cryopreserved for later analysis.
pMHC-I tetramers. Tetrameric peptide-major histocompatibility complex
class I (pMHC-I) complexes specific for HLA A2-, HLA B7-, or HLA B8-
restricted epitopes derived from HIV were produced as previously described
with minor modifications (5, 38). All tetramers were validated and titrated using
PBMCs isolated from the HIV-1-infected patients in this study; in all cases, these
reagents were conjugated to streptavidin-allophycocyanin and used as described
previously (75).
Flow cytometric assessment of CD8 T-cell function. PBMCs from HIV-
infected patients or healthy donors were thawed and cultured overnight in RPMI
1640 medium supplemented with 10% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 g/ml), and glutamine (2 mM) (R-10) prior to stimulation.
Antigens comprised an HIV-1 peptide pool containing overlapping 15-mer pep-
tides provided by the NIH AIDS Research and Reference Reagent Program
(Gag pool, 123 peptides) and HLA class I-restricted HIV or cytomegalovirus
(CMV) optimal peptides purchased from NeoMPS, France (all at an individual
peptide concentration of 2 g/ml). These peptides were as follows: HLA-A2
restricted (HIV Gag p17 residues 77 to 85 [SLYNTVATL], HIV RT residues 464
to 472 [ILKEPVHGV] and CMV pp65 residues 495 to 503 [NLVPMVATV])
HLA-B8 restricted (HIV Gag p24 residues 127 to 135 [GEIYKRWII] and HIV
Nef residues 90 to 97, [FLKEKGGL]), and HLA-B7 restricted (HIV Env gp41
residues 333 to 341 [IPRRIRQGL] and HIV Nef residues 75 to 83 [RPMTYK
AAL]). Staphylococcus enterotoxin B ([SEB] 1 g/ml; Sigma, Switzerland) was
used as a positive control in all experiments. Anti-CD107a-fluorescein isothio-
cyanate (FITC) and the costimulatory antibodies anti-CD28 and anti-CD49d at
1 g/ml each (all BD Biosciences, Switzerland) were added at the beginning of
the 5-h stimulation period. Cultures established in the absence of peptide com-
prised the negative control in each case. All experiments were carried out in the
presence of monensin A (2 M; Sigma, Switzerland) to inhibit cytokine secre-
tion. Cells were surface stained with anti-CD3-Pacific Blue and anti-CD8-peri-
dinin chlorophyll protein (PerCP) and were then stained intracellularly with
anti-gamma interferon [IFN-]-phycoerythrin (PE)-Cy7, anti-interleukin-2 [IL-
2]-PE, and anti-tumor necrosis factor alpha [TNF-]-allophycocyanin (all BD
Biosciences, Switzerland). A minimum of 50,000 events in the small live cell
scatter gate were collected. Cells were gated on CD3 CD8 T cells. Values of
negative controls (incubation in absence of antigen) were usually below 0.1%
cytokine-producing CD8 T cells. Negative values were subtracted from test
values, and values of 0.1% responding cells among CD8 T cells were consid-
ered positive. Data were collected using an LSRII flow cytometer (BD Bio-
sciences, Switzerland). Data files were analyzed using fluorescence-activated cell
sorting (FACS) DIVA Software (BD Biosciences, Switzerland).
Intracellular perforin and GrB staining and CD8 T-cell phenotyping. PB-
MCs from HIV-infected patients or healthy donors were thawed, surface stained
with anti-CD3-Pacific Blue, anti-CD8-PerCP, and anti-IL-7 receptor alpha (IL-
7R)-PE, and then stained intracellularly with anti-perforin-FITC (all BD Bio-
sciences, Switzerland). Gates for perforin stainings were set according to isotype
control stainings. Alternatively, cells were surface stained with anti-CD3-Pacific
Blue and anti-CD8-PerCP (both BD Biosciences, Switzerland) and then stained
intracellularly with anti-granzyme B (GrB)-PE (Caltag Laboratories, Switzer-
land). For CD28 and PD-1 staining, cells were stained with anti-CD3-Pacific
Blue, anti-CD8-PerCP, anti-PD-1-PE, and anti-CD28-FITC (all BD Biosciences,
Switzerland). Where appropriate, experimental setups included extracellular
pMHCI tetramer staining. Cells were kept on ice during the staining procedure
to avoid degranulation. Data were collected using an LSRII flow cytometer (BD
Biosciences, Switzerland) and analyzed using FACS DIVA Software (BD Bio-
sciences, Switzerland).
Statistical analysis. Statistical analyses were performed using SPSS for Win-
dows, version 14.0.
RESULTS
Virologic and immunologic impact of ART in study cohort.
In this study, we investigated the longitudinal impact of declin-
ing HIV-1 pVL on the phenotype and functionality of CD8 T
cells in a cohort of 25 chronically HIV-1-infected patients after
initiation of ART; we conducted similar analyses in a control
group of 12 HIV-1-infected patients who remained untreated
and in a group of 19 HIV-1 seronegative donors (Table 1).
The median pVL before onset of therapy in the study group
was 131,000 copies/ml (range, 6,680 to 2,450,000 copies/ml),
which declined significantly during ART (median, 40 copies/ml
at week 24) and remained below 50 copies/ml in treated pa-
tients throughout the study. In the control group, pVL in-
creased marginally during the observation period (median at
week 0, 49,300 copies/ml; median at week 24, 62,000 copies/
ml). After the initiation of ART, CD4 T-cell counts increased
from a median of 185 cells/l at week 0 to 315 cells/l at week
24 and to 508 cells/l at the late time point in the study group.
In the control group, CD4 T-cell counts decreased from 336
cells/l at week 0 to 275 cells/l at week 24 and reached a nadir
of 208 cells/l at the later time points (data not shown). The
percentages of CD8 T cells in the study and control groups
were stable (approximately 44% of lymphocytes) over the pe-
riod of analysis (data not shown).
We measured three different phenotypic markers (IL-7R,
PD-1, and CD28) which have been previously associated with
CD8 T-cell function. In addition, we analyzed six separate
CD8 T-cell functions to assess degranulation capacity
(CD107a), cytokine secretion (IFN-, IL-2, and TNF-) and
granule content (perforin and GrB).
Increase in IL-7R expression with prolonged time on ART.
To analyze the impact of declining pVL on the differentiation
stage of CD8 T cells, we first measured the expression of
IL-7R on CD8 T cells from study and control group patients
(Fig. 1A and B). Recent studies indicate that effector T cells
with high expression levels of IL-7R preferentially survive
and differentiate into long-lived memory cells (9, 37, 41, 59).
While the majority of antigen-experienced CD8 T cells spe-
cific for cleared pathogens express IL-7R, CD8 T-cell pop-
ulations specific for persistent viruses like Epstein-Barr virus,
CMV, and HIV contain only low levels of IL-7R-expressing
cells, thereby indicating the predominance of cells with an
effector and not a resting memory phenotype. This most likely
reflects continuous or repetitive exposure to cognate antigen
(21, 59, 74). In comparison to healthy donors, the frequency of
IL-7R expression was massively reduced in viremic HIV-
infected patients (Fig. 1A), potentially reflecting chronic im-
mune activation; approximately 80% of all CD8 T cells were
IL-7R. Importantly, after onset of successful ART and sub-
sequent decline in pVL, the frequency of IL-7R-expressing
CD8 T cells increased significantly in the study group, while
no changes were observed in the viremic control group (Fig.
1A). This indicates a slow change from an effector toward a
memory phenotype. However, even after long-term ART, the
levels of IL-7R-expressing CD8 T cells were somewhat di-
minished in treated HIV-patients compared to healthy donors
(patients at 24 weeks, 41.5%; healthy donors, 73.9%) (Fig.
1A). Consistent with these findings in the total CD8 T-cell
population, we found that the frequencies of IL-7R-express-
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ing HIV-specific CD8 T cells also increased substantially in
patients undergoing ART whereas no changes occurred in
viremic controls (Fig. 1B).
Increase in CD28 expression with prolonged time on ART.
We next analyzed the expression of the T-cell costimulatory
molecule CD28, which is down-regulated on antigen-experi-
enced, terminally differentiated CD8 T cells with restricted
proliferative potential (7, 69). Similarly to IL-7R, the fre-
quency of CD28 CD8 T cells was significantly reduced in
viremic HIV-1-infected patients compared to healthy donors
(Fig. 1C). The declining pVL after initiation of ART led to a
robust and significant increase in the frequency of CD28-ex-
pressing CD8 T cells in the study group approaching the
levels observed in healthy controls, while CD28 CD8 T cells
in the viremic control group further declined (Fig. 1C). Fur-
thermore, CD28 expression also increased on HIV-specific
CD8 T cells in study group patients but not in untreated
controls (Fig. 1E). These results strengthen our previous find-
ing that prolonged suppression of pVL by ART causes a phe-
notypic shift in CD8 T cells from an effector to a memory
type.
Decrease in PD-1 expression with declining pVL. It has
recently been shown in untreated HIV-infected patients that
increased PD-1 expression on CD8 T cells correlates not only
with pVL and functional exhaustion of CD8 T cells but also
with disease progression (23, 61, 71, 77). Therefore, we longi-
tudinally investigated the frequency of PD-1-expressing CD8
T cells in our patients. A significant decline in PD-1 expression
was observed within 24 weeks of successful ART both in total
and HIV-specific CD8 T cells (Fig. 1D and E). In contrast,
FIG. 1. Phenotypic CD8 T cell analysis. (A) Longitudinal analysis of IL-7R expression on CD8 T cells from patients in the study group
(n  number of analyzed patients at week 0 to 24/number of patients analyzed at 24 weeks), healthy donors and control group patients (n 
number of analyzed patients at week 0 to 24/number analyzed at 24 weeks). PBMC were gated on CD3 CD8 T cells. Box plots represent the
25th and 75th percentiles, black lines depict the median, whiskers indicate the 90th and 10th percentile, and dots represent outliers. Black circles
represent the median pVL (RNA copies/ml). , P 0.05; , P 0.01 (unpaired Students t test; refers to values at week 0). (B) IL-7R expression
on HIV-specific CD8 T cells. (C) CD28 expression on CD8 T cells. Cells were gated in CD3 CD8 T cells. (D) PD-1 expression on CD8
T cells. (E) Representative PD-1 and CD28 expression profiles on HIV-specific CD8 T cells at week 0 and at 24 weeks (study group: patient
02, HLA-B7 restricted, gp41 residues 333 to 341 [IPRRIRQGL]-specific CD8 T-cell response; control group: patient 33, HLA-B8 restricted, Nef
residues 90 to 97 [FLKEKGGL]-specific CD8 T-cell response). MFI, mean fluorescence intensity. wk, week.
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PD-1 expression on CD8 T cells from the viremic control
group tended to increase over the study period (Fig. 1D). Thus,
PD-1 expression on CD8 T cells is critically influenced by the
level of pVL.
Elevated levels of degranulating CD8 T cells in HIV-1-
infected patients. We next assessed the functional changes in
CD8 T cells from HIV-infected patients initiating ART and
compared them to untreated infected controls and healthy
donors. First, we analyzed the degranulation capacity of CD8
T cells from HIV-1-infected individuals by measuring the ap-
pearance of the lysosomal-associated membrane protein 1
(CD107a) on the surface of CD8 T cells following SEB and
HIV-1 Gag peptide pool stimulation (12) (Fig. 2). Although
CD107a staining is a functional readout for CD8 T cells,
previous studies have also demonstrated that this assay can be
used to determine the frequency of antigen-specific CD8 T
cells in HIV-infected individuals with a comparable accuracy
to MHC-I tetrameric complexes (12, 78). Compared to a group
of healthy donors, the frequency of CD8 T cells that degranu-
lated upon polyclonal SEB stimulation was significantly in-
creased in viremic HIV-1-infected patients, and these frequen-
cies remained increased despite declining pVL in treated
patients (Fig. 2B). No significant changes occurred in the un-
treated control group.
FIG. 2. Longitudinal assessment of the degranulation capacity of CD8 T cells. (A) Representative FACS plots and gating strategy (patient
38). PBMC were gated on small lymphocytes and subsequently on CD3 CD8 T cells. The right graphs show CD107a staining of gated cells after
mock, SEB, or Gag peptide pool stimulation. Numbers indicate the percentage of CD107 CD3 CD8 T cells. (B and C) Box plots show the
percentages of degranulating CD8 T cells; boxes indicate the 25th and 75th percentiles, black lines depict the median, whiskers indicate the 90th
and 10th percentile, and dots represent outliers. Black circles represent the median pVL (RNA copies/ml). The graphs in panel B show the
degranulation capacity of CD8 T cells from study and control groups upon SEB stimulation compared to healthy donors (n number of analyzed
patients at week 0 to 24/number analyzed at 24 weeks). , P  0.01 (unpaired students t test; refers to values at week 0). The graphs in panel
C show results of stimulation with a pool of overlapping peptides covering the complete HIV-1 Gag protein. wk, week.
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The frequency of degranulating CD8 T cells following
stimulation with the HIV-1 Gag peptide pool tended to de-
crease slightly during ART-induced viral suppression, which is
in agreement with previous studies (18, 22, 42, 55). In un-
treated controls, the frequencies of HIV-specific degranulating
CD8 T cells increased slightly over time (Fig. 2C).
Decreasing frequencies of perforin but not GrB-containing
CD8 T cells with declining pVL. Degranulation capacity on
its own is not sufficient to indicate potent cytotoxic CD8
T-cell effector function because this also depends critically on
the contents of lytic granules (reviewed in reference 48).
Therefore, we longitudinally analyzed the frequency of GrB
and perforin expression in CD8 T cells from HIV-1-infected
patients as a function of decreasing pVL in comparison to
untreated patients and healthy donors (Fig. 3).
Before onset of ART, perforin was expressed by a median of
19% of total CD8 T cells from viremic patients (Fig. 3A),
while GrB was detected in a median of 42% of total CD8 T
cells (Fig. 3C). Compared to healthy donors, frequencies of
perforin-positive CD8 T cells and to a lesser extent of GrB-
positive CD8 T cells from viremic patients were elevated;
only 6.6% and 20.3% of CD8 T cells from healthy donors
expressed perforin or GrB, respectively (Fig. 3A and C). This
indicates an expansion of CD8 T cells with effector function
in the peripheral blood of HIV-1-infected patients. However,
with prolonged ART, the frequency of HIV-specific and total
CD8 T cells expressing perforin declined significantly in the
study group, thus indicating a contraction of the CD8 T-cell
population with immediate cytolytic effector function with
ART (Fig. 3A and B). In the control group patients with
persistent viremia, no significant changes in perforin expres-
sion were observed over a similar period of time (Fig. 3A). In
contrast to the declining levels of perforin expression with
ART, we did not observe any significant changes in GrB ex-
pression in total or HIV-specific CD8 T cells over time in
either group (Fig. 3C and D).
Dynamics of cytokine secretion by CD8 T cells after onset
of ART. Next, we compared the cytokine secretion capacity of
degranulating CD8 T cells (Fig. 4) under conditions of de-
clining and suppressed pVL in study group patients, in viremic
control group patients, and in healthy control individuals. We
initially focused our analysis on the cytokine secretion capacity
of degranulating cells as we have shown previously that de-
granulation is a robust effector function to assess antigen-
reactive CD8 T cells under conditions of persistent exposure
to viral antigen (1). After SEB stimulation, a median of 35.8%
of CD107a CD8 T cells secreted IFN- in HIV-infected
patients at week 0, followed by TNF- (median, 12.1%) and
finally IL-2 (median, 8.3%). In healthy donors, however, these
frequencies were of equal magnitude (IL-2, 28.7%; IFN-,
27.1%; and TNF-, 22.4%) (Fig. 4). After initiation of ART, a
significant recovery of cytokine (IL-2 and TNF-) secretion
capacity within degranulating CD8 T cells was observed,
while IFN- secretion capacity remained constant. In sharp
contrast, no changes in IL-2 or TNF- secretion capacities
were observed in the control group where the pVL remained
constant (Fig. 4). Thus, we conclude that the increase in CD8
T-cell cytokine secretion capacity on ART reflects an overall
improvement of CD8 T-cell functionality (Fig. 4), which is
closely linked to the decline of HIV replication and thus pVL
as a surrogate for antigen load.
We confirmed that these changes in cytokine production
capacity are not confined to degranulating CD8 T cells but
also hold for total CD8 T cells. CD8 T cells from viremic
study group patients predominantly secreted IFN- (median,
5.8%) before initiation of ART (week 0), followed by TNF-
(median, 2.2%) and finally IL-2 (median, 1.4%), which is con-
cordant with previous findings (13). In contrast, healthy donors
exhibited similar frequencies of CD8 T cells that were able to
secrete IL-2 (median, 4.2%), TNF- (median, 4.1%), and
IFN- (median, 3.3%). Upon initiation of ART, the frequen-
cies of IL-2- and TNF--secreting CD8 T cells increased
continuously, leading to a statistically significant increase for
the latest time point of analysis compared to baseline (data not
shown). In contrast, the frequencies of IL-2- and TNF--se-
creting CD8 T cells remained low in the untreated control
group. The frequencies of IFN--secreting CD8 T cells also
showed a tendency to increase with declining pVL, although
this did not reach statistical significance (not shown).
Selective impairment of cytokine secretion in HIV-specific
CD8 T cells. We next analyzed whether impaired cytokine
production by CD8 T cells is independent of antigen speci-
ficity in viremic patients or whether it is preferentially found in
HIV-specific CD8 T cells. To achieve this, we compared the
cytokine expression capacity of degranulating (CD107a)
CD8 T cells from viremic patients (week 0) upon stimulation
with HIV-1 Gag pool peptides or with a CMV pp65-derived
peptide (Fig. 5). Before initiation of ART, the proportion of
degranulating CD8 T cells capable of producing IFN- or
TNF- upon HIV-1-specific stimulation was significantly re-
duced in comparison to CMV pp65 peptide stimulation, sug-
gesting a predominant functional defect in HIV-specific CD8
T cells (Fig. 5). Both HIV- and CMV-specific cells demon-
strated very low frequencies of IL-2 production, consistent with
previous studies (1, 71, 80).
We then analyzed whether the cytokine production defect in
FIG. 3. Longitudinal analysis of CD8 T-cell granule content. (A and C) Comparison of perforin and GrB expression in total CD8 T cells
from study group patients, control group patients, and healthy donors (n  number of analyzed patients at week 0 to 24/number analyzed at 24
weeks). PBMC were gated on CD3 CD8 T cells. Box plots represent the 25th and 75th percentiles, black lines depict the median, whiskers
indicate the 90th and 10th percentiles, and dots represent outliers. Black circles represent the median pVL (RNA copies/ml). , P  0.05; , P
 0.01 (unpaired students t test; refers to values at week 0). (A) Perforin expression. (C) GrB expression. (B and D) Representative FACS plots
for assessment of perforin and GrB expression in HIV-specific and total CD8 T cells. Plots in upper rows are gated on CD3 CD8 T cells.
Numbers indicate the percentages of cells in the respective quadrants. (B) Representative intracellular perforin and extracellular IL-7R staining
of HIV-specific or total CD8 T cells (patient 20, HLA-A2 restricted, Gag p17 residues 77 to 85 [SLYNTVATL]-specific CD8 T-cell response).
(D) Representative intracellular GrB staining of HIV-specific or total CD8 T cells (patient 29, HLA-A2 restricted, RT residues 464 to 472
[ILKEPVHGV]-specific CD8 T-cell response). wk, week; grzB, granzyme B.
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HIV-specific CD8 T cells was restored by ART-induced sup-
pression of HIV replication. Indeed, upon stimulation with the
HIV-1 Gag peptide pool, we observed an increase in IFN-,
IL-2, and TNF- secretion capacity in patients with long-term
suppression of HIV-1 replication (median, 114 weeks). These
increases were profound and statistically significant for IL-2
and TNF- at late time points (Fig. 6A and B). Thus, our
findings demonstrate that HIV-specific CD8 T cells are par-
ticularly impaired with regard to cytokine secretion in viremic
patients. Importantly, this functional defect is regulated by the
level of persistent antigen exposure and can be restored in vivo
by long-term reduction of pVL as a surrogate for antigen load.
Emergence of polyfunctional CD8 T cells after prolonged
ART. Next, we addressed whether the overall improvement of
cytokine production during ART was evident on a single-cell
level. We therefore assessed the simultaneous ability of CD8
T cells to execute four different effector functions: degranula-
tion, IFN-, TNF-, and IL-2 secretion. As shown in Fig. 7,
prolonged suppression of pVL by ART allows for the devel-
opment of polyfunctional CD8 T cells as assessed after SEB
or HIV-specific stimulation (Fig. 7A). In particular, prolonged
ART was associated with the appearance of CD8 T cells
exhibiting three or four simultaneous functions. In contrast, no
gain in polyfunctionality was observed in the viremic control
group either after SEB or after HIV Gag stimulation (Fig. 7B).
DISCUSSION
In the present study, we investigated longitudinal changes in
the functionality and phenotype of CD8 T cells in a cohort of
FIG. 4. Longitudinal assessment of the cytokine secretion capacity of degranulating CD8 T cells. Cytokine (IFN-, IL-2, and TNF-) secretion
capacity of degranulating (CD107a) CD8 T cells upon SEB stimulation from study group patients compared to patients from the control group
and healthy donors (n  number of analyzed patients at week 0 to 24/number analyzed at 24 weeks). Box plots represent the 25th and 75th
percentiles, black lines depict the median, whiskers indicate the 90th and 10th percentiles, and dots represent outliers. Black circles represent the
median pVL (RNA copies/ml). , P  0.05; , P  0.01 (unpaired students t test; refers to values at week 0). Data are shown for IFN- (A), IL-2
(B), and TNF- (C). wk, week.
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chronically HIV-1-infected patients on commencement of
ART. Our results clearly demonstrate that the quality of HIV-
specific CD8 T cells changes fundamentally during successful
ART. Cells acquire a phenotype of resting memory cells
(CD28 and CD127high) and exhibit reduced expression of
markers associated with dysfunction (i.e., PD-1). More impor-
tantly, CD8 T cells increase their functional repertoire par-
ticularly with respect to TNF- and IL-2 production; further-
more, a sizeable proportion of specific cells become
polyfunctional. This indicates that pVL as a surrogate for an-
tigen load has a profound and direct influence on T-cell func-
tionality. The overall improvement of CD8 T-cell function is
not due to the presence of increased frequencies of naı¨ve
CD8 T cells after prolonged ART as naı¨ve CD8 T cells are
poor cytokine producers in 5-h stimulation assays (data not
shown), and functional improvement was observed for both
SEB-reactive and HIV-specific CD8 T cells.
It has been reported previously that HIV-specific CD8 T
cells from viremic patients are impaired in cytokine production
(11, 13, 24, 46, 58, 68), and it was proposed that this might be
a consequence of persistent antigen exposure, which induces a
state of functional exhaustion. Thus, only a fraction of HIV-
specific CD8 T cells detectable by tetramer staining produced
IFN- upon stimulation (30, 46, 58, 67), and this fraction in-
creased with long-term ART (58). Here, we support and ex-
tend these findings by showing that HIV-specific CD8 T cells
from viremic patients are significantly impaired with regard to
not only IFN- but also IL-2 and TNF- production whereas
degranulation capacity (CD107a) is largely conserved.
Recently, we have reported a similar dichotomy in CD8
T-cell effector functions in chronic murine lymphocytic chorio-
meningitis virus infection, where prolonged in vivo antigen
exposure led to severely impaired cytokine production while
degranulation and cytolytic activity were maintained at a cel-
lular level (1, 68). Furthermore, a detailed cross-sectional anal-
ysis of various CD8 T-cell functions in HIV-infected individ-
uals showed that degranulation was a relatively robust effector
function in most cases (13). In the present longitudinal study
we demonstrate that this selective dysfunction is dependent on
the level of antigen, since ART-induced suppression of HIV
replication led to in vivo restoration of IL-2, IFN-, and
TNF- secretion capacity in degranulating HIV-specific and
bulk CD8 T cells. Whether this overall restoration of cytokine
secretion capacity in CD8 T cells is caused by a functional
improvement on a single-cell level or whether it is due to
preferential survival and expansion of cytokine-producing cells
is at present unclear.
The overall functional restoration of CD8 T cells seems to
be a slow process, which became clearly apparent only after
more than 2 years of complete viral suppression. Therefore,
previous studies analyzing several CD8 T-cell functions simul-
taneously may have missed such an effect of ART since the
longitudinal follow-up of these patients may have been too
short (13). In addition, addressing these questions in a cross-
sectional design may be less appropriate because very large
patient groups would be needed to compensate for the sub-
stantial individual variation of these parameters.
The most crucial question raised by our data concerns the
significance of the observed changes in CD8 T-cell function-
ality for the control of HIV replication. We have not formally
tested this possibility by interruption of ART in the present
study since current treatment guidelines do not favor treat-
ment interruptions. However, it seems highly unlikely that HIV
control would be enhanced in these patients after cessation of
ART despite the presence of polyfunctional cells. Several large
studies in comparable patient populations with chronic HIV
infection have firmly established that HIV control is not im-
proved after interruption of prolonged ART; the viral set point
in these studies was usually very similar before the onset and
after the cessation of ART (27, 28, 36, 54, 56). Therefore, the
question remains whether polyfunctionality of T cells is indeed
a predictive correlate of protective immunity in HIV infection
or whether it mainly reflects reduced in vivo antigen exposure,
a milieu which seems to be a prerequisite for the development
of such cells both in humans and in mice (1, 13, 34, 49, 76). Our
data clearly support the latter, and previous data on polyfunc-
tional T cells in LTNP could be interpreted similarly (13).
Nevertheless, for progress to be made toward a T-cell-based
vaccine, it is highly desirable that a solid correlate of protective
immunity can be identified. Although a recent HIV vaccination
trial unfortunately had to be halted prematurely due to lack of
efficacy, careful immunological analyses in these individuals
may help to clarify whether the functional profile of T cells
constitutes such a correlate of protection or not (6).
FIG. 5. Comparison of the cytokine secretion capacity of HIV- and CMV-specific CD8 T cells at week 0. Cytokine secretion capacity of
degranulating (CD107a) CD8 T cells from viremic patients (week 0, n  8) exhibiting an HLA-A2-restricted CMV, pp65 residues 495 to 503
(NLVPMVATV)-specific CD8 T-cell response. PBMCs were stimulated with the CMV pp65 peptide or with the Gag pool peptides. Box plots
represent the 25th and 75th percentiles; black lines depict the median. P, unpaired students t test.
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Comparable to HIV-specific CD8 T cells, the functionality
and the phenotype of HIV-specific CD4 T cells are also
influenced by the level of antigen exposure in vivo. In LTNP
and patients on therapy, the phenotype and cytokine produc-
tion capacity of HIV-specific CD4 T cells was comparable to
CD4 T-cell responses directed against non-HIV antigens; in
contrast, HIV-specific CD4 T cells from untreated viremic
patients showed reduced proliferation and IL-2 production
capacity and exhibited an effector phenotype (26, 35, 39, 50, 70,
79).
The exhaustion of cytokine secretion capacity in CD8 T
cells is inversely correlated with the frequency of PD-1-ex-
pressing CD8 T cells, indicating that PD-1 expression is a
marker for an exhausted CD8 T-cell population. It has been
reported previously that PD-1 expression levels on HIV-spe-
cific CD8 T cells are correlated with pVL and that blockade
of the PD-1/PD-1L pathway leads to restoration of CD8
T-cell function in vitro (23, 61, 71, 77). However, because we
observed that the frequency of PD-1-positive CD8 T cells and
dysfunctionality are both regulated by the level of viremia, it
seems more likely that increased PD-1 expression and cellular
dysfunction are rather the result than the cause of high vire-
mia.
Taking these results together, we show here that a high level
of HIV viremia causes a selective functional impairment of
HIV-specific CD8 T cells with regard to cytokine secretion
but not with respect to degranulation capacity and GrB expres-
sion (68). The fact that prolonged treatment with ART allowed
the restoration of cytokine secretion capacity by CD8 T cells
suggests that the level of antigen exposure in vivo is the main
cause of CD8 T-cell dysfunction. Furthermore, persistent
exposure to antigen led to the differentiation of CD8 T cells
with an effector phenotype, and a sustained decrease in pVL as
a surrogate for antigen load induced a transition toward a
memory phenotype with a polyfunctional profile. Whether
these polyfunctional memory-type CD8 T cells are able to
FIG. 6. Longitudinal changes in cytokine secretion capacity of HIV Gag-specific CD8 T cells. (A) Representative FACS plots for assessment
of degranulation, IFN-, IL-2, and TNF- production upon mock or Gag peptide pool stimulation (patient 02). Plots are gated on CD3 CD8
T cells. The upper graphs show staining results from week 0, and the lower graphs show staining results at 24 weeks. Numbers indicate the
percentages of cells in the respective quadrants. (B) Longitudinal analysis of cytokine production of degranulating CD8 T cells upon stimulation
with the HIV-1 Gag peptide pool (n  number of analyzed patients at weeks 0 to 24/number analyzed at 24 weeks). Box plots represent the 25th
and 75th percentiles, black lines depict the median, whiskers indicate the 90th and 10th percentiles, and dots represent outliers. P, unpaired
students t test. wk, week.
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mediate any superior protection is unlikely based on our dis-
appointing experiences with treatment interruption trials in
chronic HIV infection. However, it is conceivable that the
polyfunctional T cells that arise spontaneously in untreated
HIV infection in LTNP are different from the polyfunctional T
cells that develop under prolonged ART; this is a testable
hypothesis that merits further investigation.
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